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Abstract
Alzheimer’s disease (AD) pathology precedes the onset of clinical symptoms by several decades. Thus, biomarkers are 
required to identify prodromal disease stages to allow for the early and effective treatment. The methoxy-X04-derivative 
BSC4090 is a fluorescent ligand which was designed to target neurofibrillary tangles in AD. BSC4090 staining was previ-
ously detected in post-mortem brains and olfactory mucosa derived from AD patients. We tested BSC4090 as a potential 
diagnostic marker of prodromal and early AD using olfactory mucosa biopsies from 12 individuals with AD, 13 with mild 
cognitive impairment (MCI), and 10 cognitively normal (CN) controls. Receiver-operating curve analysis revealed areas 
under the curve of 0.78 for AD versus CN and of 0.86 for MCI due to AD versus MCI of other causes. BSC4090 labeling 
correlated significantly with cerebrospinal fluid levels of tau protein phosphorylated at T181. Using NMR spectroscopy, 
we find that BSC4090 binds to fibrillar and pre-fibrillar but not to monomeric tau. Thus, BSC4090 may be an interesting 
candidate to detect AD at the early disease stages.
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Introduction
Alzheimer’s disease (AD) is characterized by deposition of 
amyloid plaques and neurofibrillary tangles (NFTs) com-
posed of aggregated tau protein [14, 21, 38]. AD pathol-
ogy begins decades before clinical symptoms emerge [7, 
23, 35]. Therefore, therapeutic interventions to prevent or 
slow down disease progression should start at the earliest 
possible time point. Thus, there is an urgent need for novel 
biomarkers to detect AD pathology in the prodromal or even 
preclinical disease stage. Whereas substantial progress has 
been achieved with PET tracers detecting amyloid plaques, 
biomarkers indicating tau pathology in AD are restricted 
to high levels of phosphorylated tau in cerebrospinal fluid 
(CSF).
Olfactory impairment is observed in many neurodegen-
erative disorders including AD [6, 16]. It precedes the onset 
of clinical symptoms by many years, constitutes a risk factor 
for mild cognitive impairment (MCI), and is associated with 
rapid cognitive decline [15, 40] and a high burden of tau 
pathology. AD pathology has been observed in the olfactory 
bulb but also in peripheral olfactory epithelia (OE) [4]. For 
example, tau immunoreactive dystrophic neurites [2, 37], 
pathologically phosphorylated tau and fibrillar tau deposits 
[3, 27, 43] were detected in post-mortem and bioptic OE 
tissue [36] derived from AD patients. However, the sensitiv-
ity to detect AD and the specificity to distinguish AD from 
controls were low. Of note, immunoreactivity against phos-
phorylated tau was absent in OE biopsies from five patients 
with mild and moderate AD and may thus emerge only at 
later disease stages [22].
The fluorescent methoxy-XO4 derivative BSC4090 binds 
to NFTs in human AD brains with high affinity and specific-
ity and colocalizes with NFT-tau phosphorylated at S202/
T205 (AT8) [13]. BSC4090 also labels post-mortem OE 
from neuropathologically confirmed AD patients [13].
We, therefore, evaluated the potential of BSC4090 to 
detect tau pathology in OE biopsies of individuals in the 
early and prodromal AD stages.
Materials and methods
Standard protocol approvals, registrations, 
and patient consents
After written informed consent, nasal mucosa biopsies were 
collected at the University Medical Center Göttingen, Ger-
many. Between 2012 and 2014, 12 subjects with a diagnosis 
of AD, 13 with a diagnosis of MCI, and 10 cognitively nor-
mal controls (CN) underwent biopsy (IRB approval 25/2/12 
by the local ethics committee). All procedures involving 
human participants were in accordance with the 1964 Hel-
sinki declaration and its later amendments.
CSF collection
Cerebrospinal fluid (CSF) samples were obtained from nine 
subjects with AD, 13 with MCI, and two from the CN group. 
All CSF samples were retrieved by lumbar puncture, col-
lected in polypropylene tubes, and centrifuged at 2000×g 
for 10 min at room temperature. Supernatants were aliquoted 
and frozen at − 80 °C within 30 min of the procedure’s 
completion.
Assessments
AD patients fulfilled the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzhei-
mer’s Disease and Related Disorders Association (NINCDS-
ADRDA) criteria for probable AD. MCI diagnosis was 
based on the recommendations from the National Institute 
on Aging–Alzheimer’s Association workgroups on diag-
nostic guidelines for Alzheimer’s disease (NIA–AA) [1]. 
According to the NIA–AA criteria, a diagnosis of MCI due 
to AD was given based on the presence of AD biomark-
ers in CSF. Subjects fulfilling the clinical and neuropsy-
chological criteria of MCI were classified as MCI due to 
AD if either CSF tau or CSF amyloid-β 42 or both were in 
the pathological range [1] with CSF tau levels above and/or 
CSF amyloid-β 42 concentrations below the cutoff. Cut-off 
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values were based on Dumurigier et al. [17], with 568 pg/mL 
as cutoff for CSF amyloid-β 42 and 307 pg/mL for CSF tau.
All participants with AD or MCI underwent brain MRI or 
cranial computer tomography imaging to rule out the other 
causes of dementia or cognitive impairment.
Neuropsychological assessments
AD, MCI, and CN control subjects were assessed with the 
Consortium to establish a registry for Alzheimer’s disease 
(CERAD) Plus neuropsychological test battery [18, 32]. 
MCI was defined as the combination of memory complaints 
plus a performance of 1–1.5 standard deviations below the 
age norm on at least one cognitive domain, while activi-
ties of daily living were preserved [41]. CN controls were 
recruited from the departments of urology and otorhinolar-
yngology, head and neck surgery at the University Medical 
Center Göttingen, and included patients with prostate and 
bladder cancer or chronic sinusitis who underwent surgery 
with or without spinal anesthesia. Specimens of cognitively 
normal controls were collected from the endonasal mucosa 
in the olfactory area where endoscopically no sign of chronic 
sinusitis was detected. Patients recruited from the depart-
ment of urology had no history of nasal pathology. Patients 
recruited from the department of otorhinolaryngology, head 
and neck surgery had mild chronic sinusitis without nasal 
polyps affecting single sinuses due to anatomical abnormali-
ties (e.g., deviated nasal septum narrowing the ostiomeatal 
complex). This had no impact on the mucosa in the region 
where specimens have been collected. None of the CN con-
trols fulfilled criteria for MCI or dementia nor suffered from 
a neurodegenerative disease. For patients’ characterization, 
please refer to supplementary Table S1.
Sniffin sticks test
Olfactory function was evaluated using the Sniffin Sticks 
test battery consisting of a discrimination and an identifi-
cation test [10]. For odor presentation, the cap of the pen 
was removed by the investigator for approximately 3 s and 
the odorized tip was placed approximately 2 cm in front 
of the subject´s nostrils. All olfactory tests were performed 
bilaterally.
Biopsies of nasal mucosa
Specimens were taken randomly or at the side that was most 
easily accessible if a deviated nasal led to a narrow septum 
on one side. Local anesthesia was obtained by placing a 
cotton wool with Tetracaine hydrochloride 2% and Xylo-
metazoline hydrochloride 0.1% in the nasal cavity above the 
middle turbinate. Consequently, an angled Blakesley for-
ceps was introduced through the naris and advanced between 
the septum and middle turbinate. The cutting edge was 
pressed against the olfactory mucosa and withdrawn with 
the mucosal specimen. The specimens were immediately 
placed on 4% paraformaldehyde in PBS for 1–2 days at 4 °C.
Immunohistochemistry and BSC4090 labeling
Fixed tissue was embedded in paraffin and serially sectioned 
at 1 ∝m intervals. Sections were deparaffinised and boiled 
for 30 min in 10 mM citrate buffer (pH 6.0). After 10 min 
incubation in 3%  H2O2 and blocking for 30 min in 10% 
fetal calf serum (FCS), probes were stained with antibod-
ies against hyperphosphorylated tau (AT8, 1:1000, Thermo 
Scientific; Germany). Sections were treated with biotin-con-
jugated anti-mouse immunoglobulins (Abcam) which were 
visualized by a horseradish peroxidase-diaminobenzidine 
(Sigma-Aldrich, Germany) reaction. All sections were addi-
tionally stained with hemalaun following standard protocols.
The divinylpyridazine derivate 4-((1E)-2-(6-(4-
(dimethylamino)styryl)pyrimidin-4-yl)vinyl)-N,N-dimeth-
ylbenzylamin BSC4090 was synthesized and used for 
staining of adjacent sections as described previously [12]. 
Briefly, deparaffinized sections were incubated for 10 min 
at room temperature in 1 g/l BSC4090 dissolved in metha-
nol. Sections were then washed for 1 min in distilled water 
and incubated in 1% acetic acid for 15 min at room tem-
perature, followed by two 1 min washing steps in distilled 
water. Bowman glands were identified by their characteristic 
morphology.
Microscopy
Fluorescence images were acquired with a confocal laser 
scanning microscope (Leica SP2, Leica, Germany). 
BSC4090 was excited at 488 nm with identical laser settings 
for all the samples. DAB stained sections and images for 
quantitative analysis of BSC4090 were acquired at an inverse 
epifluorescence microscope (MEA53100 Ti-E, Nikon, Düs-
seldorf, Germany). Large-scale images to cover the complete 
section were composed by stitching single images, using the 
NIS Elements AR software (Nikon, Düsseldorf, Germany).
CSF analysis
The analysis of CSF biomarkers was performed by solid-
phase enzyme immunoassays for amyloid-β1-42, total tau, 
and p-tau 181 (Innotest, Fujirebio Europe).
Data analysis
Data analysis was performed by a rater blinded to the 
diagnosis. For all BSC4090 labeled sections, adjacent sec-
tions were stained with haemalaun to verify the presence 
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of olfactory Bowman glands. At least three different sec-
tions were analyzed per participant. The BSC4090 ratio was 
calculated as the number of BSC4090 positive to the total 
number of Bowman gland cells from each section.
NMR spectroscopy
Proteins and chemicals
pNG2 plasmid with inserted coding sequences of the full-
length tau isoform hTau40 and tau construct K18 (amino 
acids 244–372) were transformed into E. coli strain 
BL21(DE3) (Merck-Novagen, Darmstadt) [20]. Proteins 
were purified as described previously [5]. Uniformly 15N 
enriched htau40 sample was prepared by growing E. coli 
bacteria in minimal medium containing 1 g/l of 15NH4Cl 
according to the established protocols [33, 34]. The com-
pound BSC4090 was synthesized in-house [13].
Protein aggregation
Aggregation of K18 was induced by incubating 10 µM 
soluble K18 and 1 mM DTT by adding the anionic cofac-
tor heparin (Sigma, Germany) in 50 mM sodium phosphate 
buffer, pH 6.8 at 37 °C, with a molar ratio of K18 to heparin 
of 4:1. The solution was incubated at 37 °C before NMR 
experiments for 30 min and continued at 25 °C for ∼ 3 days 
during the course of NMR experiment. A parallel sample 
was used to monitor the formation of aggregates by electron 
microscopy.
Electron microscopy
Samples containing aggregates of K18 were diluted, depos-
ited onto carbon-coated copper mesh grids and negatively 
stained with 1% (w/v) uranyl acetate. Samples were exam-
ined using a Philips CM 120 BioTwin transmission electron 
microscope (FEI, Eindhoven, The Netherlands). Pictures 
were taken with a TemCam F416 CMOS camera (TVIPS, 
Gauting, Germany).
NMR spectroscopy
BSC4090 was dissolved in DMSO-D6 at a concentration 
of 10 mM. NMR measurements were performed in 50 mM 
sodium phosphate buffer, pH 6.8, 10%  D2O and 3% DMSO-
D6. Two-dimensional (2D) 1H-15N heteronuclear single 
quantum coherence (HSQC) experiments [8, 9, 11] of tau 
in the presence and absence of the compound BSc4090 
were recorded at 5 °C on a 700 MHz Bruker spectrome-
ter equipped with a cryoprobe prodigy. The spectra were 
processed using Topspin 3.1 (Bruker) and analyzed using 
Sparky 3.114 (T. D. Goddard and D. G. Kneller, http://www.
cgl.ucsf.edu/home/spark y).
To probe the interaction of the ligand BSC4090 with the 
aggregates/fibrils of K18 (tau244-372), saturation-transfer 
difference (STD) NMR spectra [25, 28] of BSC4090 with 
and without K18 aggregates were recorded. The concentra-
tions of the ligand and K18 were 150 µM and 10 µM, respec-
tively. 1D STD NMR spectra were recorded at 25 °C on a 
600 MHz spectrometer equipped with a cryoprobe using a 
series of 40 equally spaced 50 ms Gaussian-shaped pulses 
for saturation of the protein, with a total saturation time of 
1.5 s. To saturate the protein protons, on- and off-resonance 
frequencies were set to − 0.5 ppm and 60 ppm, respectively.
Results
Collection of olfactory mucosa biopsies
To test the potential of BSC4090 as a diagnostic antemortem 
marker of AD pathology, we obtained biopsies from study 
participants diagnosed with either AD, MCI or from CN 
controls. The cognitive state of each individual was assessed 
by the CERAD Plus test battery [32].
Intranasal biopsies were well tolerated. No adverse events 
such as excessive bleeding, pain, or olfactory nerve injury 
were observed. Tissue specimens were cut into 1 µm sec-
tions and every tenth section was labeled with BSC4090. 
Sections with less than 5 Bowman glands were excluded 
from analysis. Tissue volumes of at least 2 mm diameter and 
correct location of the biopsy from the nasal cavity above 
the middle turbinate allowed the quantification of gland 
pathology and were obtained after training of the biopsy 
procedure. An overview of demographic data including age, 
gender, and MMSE is given in Supplementary Table S1.
BSC4090 labeling of mucosal biopsies distinguishes 
between AD and CN controls
Evaluation of BSC4090 labeling was carried out by a rater 
blinded to the diagnosis. All 12 mild AD cases showed 
strong BSC4090 labeling of Bowman glands (Fig. 1a, b). 
Frequently, BSC4090 staining was restricted to several, 
mostly adjacent cells or single cells within Bowman glands. 
BSC4090 labeling was mainly homogenous or granular 
but never fibrillar. This staining pattern is similar to that 
described for post-mortem AD OE [12, 13].
BSC4090 staining was also detected in eight out of ten 
CN controls, albeit to a markedly lower extent (Fig. 1c). 
We next quantified the ratio of BSC4090 positive to the 
total number of Bowman gland cells from at least three 
different sections per biopsy (Fig. 1d). BSC4090 ratios 
were significantly higher in the AD group as compared to 
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the CN group (AD: mean 0.18, n = 12; CN: mean 0.073, 
n = 10, p = 0.002; Mann–Whitney U test) (Fig.  1d). 
Receiver-operating curve (ROC) analysis revealed that the 
BSC4090 ratio distinguishes between AD and CN controls 
with 75% sensitivity and a specificity of 80%. The area 
under the curve (AUC) was 0.778 (p = 0.0125) (Fig. 1e). 
Of note, one participant from the CN group reached a 
BSC4090 ratio of 0.377 far above the mean value of this 
group (0.076). It is tempting to speculate that this finding 
may indicate a preclinical stage of AD, although CSF data 
were not available for this participant to further support 
this notion.
MCI due to AD is detected by BSC4090 staining
Based on CSF amyloid-β42 and tau levels, we divided the 
MCI group into MCI due to AD (n = 6) and MCI with other 
causes (n = 7) (Fig. 2a, b). The BSC4090 ratio in the MCI 
due to AD group was significantly higher than in the MCI 
with other causes’ group (MCI due to AD, mean 0.158; 
MCI other causes, mean 0.060, p = 0.0385; Mann–Whitney 
U test) (Fig. 2b). Of note, the BSC4090 ratios for MCI with 
other causes were similar to those of the CN group (MCI 
other causes, mean 0.060, compared to CN, mean 0.073, 
p = 0.928, Mann–Whitney U test). BSC4090 ratios detected 
Fig. 1  BSC4090 distinguishes 
between Alzheimer tissue (AD) 
and controls (CN). a Over-
view of BSC4090 labeling in 
olfactory mucosa of bioptic 
AD OE tissue. Scale bar 200 
µm. b Higher magnification of 
BSC4090 positive Bowman 
glands in olfactory mucosa of 
bioptic AD OE tissue. Scale bar 
70 µm. c No BSC4090 labeling 
in a biopsy of a cognitively 
normal (CN) control (CSF 
biomarker negative). Scale bar 
70 µm. d Box blot of BSC4090 
ratios (= BSC4090 positive OE 
cells versus all OE cells) of AD 
and CN controls; p = 0.002. 
e ROC curve analysis was 
performed to evaluate the diag-
nostic performance of BSC4090 
ratios to distinguish AD from 
CN controls (area under the 
curve AUC = 0.778, p = 0.0125)
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AD due to MCI with a sensitivity of 100% and distinguished 
it from MCI with other causes with a specificity of 71.4%. 
ROC analysis revealed an AUC value of 0.857 (p = 0.0015) 
(Fig. 2c). We then combined AD and MCI due to AD into 
an “AD pathology group” and MCI with other causes and 
CN into a joint “control group”. Figure 2d shows box plots 
of these two groups with a mean BSC4090 ratio of 0.172 in 
the “AD pathology group” and 0.068 in the “control group” 
(p = 0.002, Mann–Whitney U test) (Fig. 2d). The sensitiv-
ity of BSC4090 ratios to detect AD pathology amounted to 
77.8% and the specificity was 76.5%. ROC analysis revealed 
an AUC of 0.810 (p < 0.0001) (Fig. 2e).
BSC4090 ratio correlates with CSF levels of ptau 181
We next tested whether the percentage of BSC4090 posi-
tive OE cells increases with disease progression. To this 
end, we correlated BSC4090 ratios to CSF levels of tau 
as a marker of neuronal injury and tau phosphorylated 
at T181 (ptau181) as a more specific measure of AD tau 
pathology [19]. However, we did not observe a significant 
correlation between CSF levels of total tau and BSC4090 
ratios (Fig. 3a). In contrast, CSF concentrations of ptau181 
were positively correlated with the BSC4090 ratio over 
all diagnostic groups (Pearson correlation r = 0.438846, 
p = 0.0466, n = 21) (Fig.  3b). BSC4090 ratios did not 
correlate with CSF amyloidβ-42 concentrations (Pear-
son correlation 0.20, p = 0.35, n = 22) (Fig. 3c) nor with 
Mini-Mental State Examination (MMSE) scores (Pear-
son correlation − 0.22, p = 0.29, n = 35, all diagnostic 
groups) (Fig. 2d). Pearson correlation between MMSE 
and BSC4090 ratios amounted to − 0.07 in the combined 
AD + MCI due to AD group (n.s., n = 17, data not shown) 
and to − 0.05 in the AD group (n.s., n = 11, data not 
shown). MMSE scores may not accurately reflect cognitive 
impairment in MCI due to ceiling effects. Unfortunately, a 
possible correlation of CERAD test battery subscores with 
BSC4090 ratios could not be calculated due to the low 
number of subjects in the MCI due to AD group (n = 6) 
and bottom effects in the AD group (data not shown). 
Fig. 2  BSC4090 distinguishes between MCI due to AD and MCI 
caused by other reasons. a BSC4090 staining of Bowman glands 
in olfactory mucosa biopsies of participants with MCI due to AD. 
Scale bar 70 µm. b Box blot analysis of BSC4090 ratios of olfactory 
mucosa biopsies of participants with MCI due to AD (upper bar) ver-
sus MCI caused by other reasons (lower bar); p = 0.038. c ROC curve 
of bioptic olfactory mucosa BSC4090 ratios to distinguish MCI due 
to AD from MCI caused by other reasons (AUC 0.857, p = 0.0015). d 
Boxplot of BSC4090 ratios in olfactory mucosa biopsies of AD and 
MCI due to AD (AD pathology group) compared to the MCI caused 
by other reasons and CN group (control group) (p = 0.002). e ROC 
analysis of BSC4090 ratios to distinguish between AD and MCI due 
to AD (AD pathology group) compared to the MCI caused by other 
reasons and CN group (control group)(AUC 0.81, p < 0.0001)
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Interestingly, BSC4090 ratios did also not correlate with 
olfactory dysfunction as quantified by the sniffin sticks test 
(Pearson correlation − 0.088, p = 0.72, n = 19) (Fig. 3e), 
although it cannot be excluded that olfactory dysfunction 
in the AD group rather reflects cognitive impairment than 
the ability to detect the odor. Importantly, BSC4090 ratios 
did not significantly correlate with age in the joint CN and 
MCI non AD group, indicating that age per se is not the 
reason for the higher values observed in the AD and MCI 
due to AD groups (data not shown).
Fig. 3  BSC4090 ratios correlate with CSF concentrations of p-tau 
181. a No correlation of CSF tau concentrations with corresponding 
BSC4090 ratios in olfactory mucosa biopsies. Pearson correlation 
coefficient r = 0.333, p = 0.129, n = 22 across all diagnostic groups 
for which CSF was available. b BSC4090 ratio of olfactory mucosa 
biopsies blotted against the corresponding CSF concentration of 
tau phosphorylated at T181, n = 21 across all diagnostic groups for 
which CSF was available. Pearson correlation coefficient r = 0.439, 
p = 0.0466. c No correlation of CSF amyloid-β42 concentrations and 
BSC4090 ratios. Pearson correlation coefficient r = 0.333, p = 0.129, 
n = 22 across all diagnostic groups for which CSF was available. d No 
correlation between MMSE scores and BSC4090 ratios. Pearson cor-
relation coefficient r= − 0.271, p = 0.117. n = 35 across all diagnostic 
groups for which MMSE scores were available. e No correlation of 
sniffin sticks scores with BSC4090 ratios. Pearson correlation coef-
ficient r = 0.063, p = 0.798. n = 19 across all diagnostic groups for 
which sniffin sticks scores were available
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BSC4090 binds to pre‑fibrillar and fibrillar tau
Since the BSC4090 staining pattern in Bowman glands did 
not resemble fibrillar morphology, we wondered whether 
BSC4090 would detect pre-fibrillar tau. Towards this end, 
we performed NMR spectroscopy of recombinant full-length 
tau (htau40, suppl. Fig. S1) with and without BSC4090. 1H-
15N HSQC NMR spectra indicated that BSC4090 does not 
bind monomeric tau (Fig. 4a–c). In contrast, STD spectra 
of tau fibrils, which were assembled from the four repeat 
region of recombinant human tau (K18, suppl. Fig. S1) 
in vitro and either measured in the absence or presence of 
BSC4090, suggested the binding of BSC4090 to fibrillar tau 
(Fig. 4d–g). The observed STD signals arise only from the 
protons of BSC4090 involved in binding (Fig. 4f). Compari-
son of STD NMR spectra of K18 measured in the presence 
of BSC4090 at different time points during in vitro aggrega-
tion revealed no major differences between K18 incubated 
for 2, 20 or 46 h (Fig. 4g). As shown by electron microscopy, 
K18 readily formed filaments after 46 h, whereas no filamen-
tous structures were detectable after 2 h of incubation (suppl. 
Fig. S2). This indicates that BSC4090 also binds pre-fibrillar 
intermediates of tau in addition to fibrillar tau aggregates.
Discussion
Here, we find that the methoxy-X04 derivative BSC4090 
detects tau pathology in OE biopsies already in the early 
disease stages such as MCI. In our pilot study, the ratio 
of BSC4090 positive Bowman gland cells distinguishes 
both AD dementia and MCI due to AD from cognitively 
unaffected controls and MCI caused by other diseases than 
AD. Furthermore, the BSC4090 ratio correlates with the 
CSF concentrations of phosphorylated tau (ptau181), a 
marker of AD-related tau pathology. Thus, BSC4090 stain-
ing of olfactory mucosa biopsies could be a potential bio-
marker for the detection of tau in prodromal and early AD 
and probably even in preclinical disease stages, especially as 
the procedure is cost-effective and safe. We did not observe 
any serious side effects and olfactory mucosa is easily acces-
sible by transnasal biopsy in an outpatient setting within an 
approximately 30 min time period. Analysis of BSC4090 
ratios resulted in the AUC values comparable to that of 
established CSF biomarkers and both sensitivity and speci-
ficity of BSC4090 could be further optimized by chemical 
modification. Importantly, BSC4090 labeling was already 
positive in the early disease stages.
Several previous studies support the notion that olfactory 
mucosa may reflect pathology of the central nervous sys-
tem, e.g., in Parkinson’s disease, schizophrenia, and rodent 
tauopathy models [26, 31, 39, 42]. Interestingly, Moon et al. 
found higher levels of miRNA-206 in olfactory mucosa in 
MCI and even more in manifest AD as compared to controls, 
thus supporting the suitability of olfactory mucosa tissue as 
a possible biomarker [30].
The high proportion of cognitively normal individu-
als who showed at least some BSC4090 positive OE cells 
could partially be explained by preclinical AD pathology in 
the CN group. Based on a recent meta-analysis including 
2914 subjects with normal cognition, Jansen et al. reported 
a 10–44% prevalence of AD pathology defined by either 
positive amyloid-β PET imaging or pathological CSF bio-
markers in the age group between 50 and 90 years [24]. 
Autopsy studies revealed even higher rates of AD pathology 
in cognitively normal individuals, ranging from 10% to as 
much as 60% [29].
One of the limitations of our study is the lack of clini-
cal longitudinal follow-up data to assess potential conver-
sions from MCI to AD or cognitive decline from CN to MCI 
and/or AD. As clinical follow-up data were not available 
in all the cases and the maximum follow-up interval was 2 
years, we had to rely on a CSF biomarker-based distinction 
between MCI due to AD and MCI due to other causes [1]. It 
is likely that longitudinal follow-up data on MCI progression 
would have resulted in a better specificity of the BSC4090 
marker, as would have post-mortem verification of diagno-
ses. During the 2 year period following this study, two of the 
six subjects in the MCI due to AD group clinically converted 
to AD dementia. Both showed the initial BSC4090 ratios 
well above the cut-off value (0.065) with BSC4090 ratios 
of 0.392 and 0.87, respectively. It would have been interest-
ing to follow whether other participants in the MCI and CN 
groups with BSC4090 ratios above the cut-off value would 
later on progress towards AD dementia. Another limitation 
Fig. 4  BSC4090 binds to fibrillar and pre-fibrillar tau. a, b Two-
dimensional 1H-15N HSQC NMR and one-dimensional 1H NMR 
spectra of full-length, 4-repeat tau (htau40) with and without 
BSC4090. An overview on recombinant tau constructs is given in 
suppl. Fig. S1. Htau40 spectra are depicted in red and htau40 with 
BSC4090 in blue. Gray arrows indicate 1H NMR signals originat-
ing from BSC4090. c NMR signal intensity ratios of cross peaks in 
the two-dimensional 1H-15N HSQC NMR spectra of htau40 with 
and without BSC4090 were above 0.9 (dashed red line). d Electron 
micrograph (EM) of K18 fibrils generated by co-incubation of mon-
omeric K18 with heparin. Scale bar 150  nm. e Identification of the 
protons in BSC4090 involved in binding with K18 fibrils. Compari-
son of the 1D NMR spectrum of K18 monomers (green) with the 1D 
(red) and STD NMR spectra (blue) of K18 fibrils in the presence of 
BSC4090. f Comparison of STD NMR spectra of K18 fibrils with 
and without BSC4090. Blue: K18 fibrils BSC4090 STD, magenta: 
K18 fibrils STD, green: K18 monomers STD, black: BSC4090 STD. 
g Comparison of STD NMR spectra during fibril formation. K18 was 
incubated with heparin for 2 h (blue), 20 h (red), and 46 h (green). 
Fibril formation was tested by EM, which detected no fibrillar tau 
after 2  h in contrast to abundant fibril formation after 46  h (suppl. 
Fig. S1). STD NMR spectra indicate that BSC4090 binds to K18 co-
incubated with heparin for 2 h, e.g., in the absence of fibrils, whereas 
BSC4090 does not bind to K18 monomers (f)
◂
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of our study is the small cohort size. Clearly, our results 
warrant a biomarker-aided, prospective, and longitudinal 
cohort with a higher number of participants, ideally with 
post-mortem verification of diagnoses, to further validate 
our findings.
In OE, the staining pattern of BSC4090 was never 
fibrillar and also negative for Thioflavin T which binds to 
β-sheet structures present in amyloid-β or tau fibrils (data 
not shown). As our in vitro NMR data suggest that BSC4090 
can bind to both, fibrillar and pre-fibrillar tau species, but 
not to monomeric tau, BSC4090 positive tau in OE is most 
likely pre-fibrillar. Binding of BSC4090 to pre-fibrillar tau 
aggregates may also explain why BSC4090 detects very 
early stages of disease pathology.
In an in vitro assay to test BSC4090 binding affinities to 
recombinant tau and amyloid-β aggregates, the IC50 values 
for BSC4090 were 4 and 54 nM, respectively [13]. This indi-
cates that the methoxy-X04 derivative BSC4090 has a high 
affinity and selectivity for aggregated tau versus amyloid-β 
fibrils. We observed partial colocalisation of BSC4090 with 
tau phosphorylated at S202/T205 (AT8) (suppl. Fig. S3). 
However, we could not detect amyloid-β pathology in our 
OE biopsies as immunostaining with 6E10 antibody against 
amino acids 3–8 of the amyloid-β peptide revealed no 6E10 
positive olfactory epithelial cells (data not shown). We can-
not rule out that BSC4090 labeling of OE glands is caused 
by unspecific binding of BSC4090 to other proteins than tau, 
although, in post-mortem brain, BSC4090 labeling patterns 
resembled the typical morphology of NFTs and colocalized 
with AT8 tau staining [13].
Conclusions
Although the number of subjects in our study is limited and 
a longitudinal observation of disease progression would 
have been desirable, we provide the evidence that (1) OE 
biopsies are a feasible diagnostic approach, (2) BSC4090 
positive pathology is present in OE in prodromal and clini-
cal AD and (3) BSC4090 may be applicable to ante mortem 
diagnosis and even may bear the potential to be employed 
as a prognostic marker in prodromal and preclinical AD. 
However, biomarker-aided longitudinal cohorts are required 
to better evaluate the diagnostic and prognostic potential of 
BSC4090 and other methoxy-XO derivatives, as well as in-
depth analysis of potentially unspecific binding sites.
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